Lilly and Incyte’s atopic dermatitis drug shows promise at Phase 3

Phase 3

Eli Lilly and Incyte have pulled back the curtain on Phase 3 data on their oral selective JAK inhibitor baricitinib as a treatment for moderate to severe atopic dermatitis in adult patients.

The findings showed that a clinically significant proportion of the trial’s participants taking either 1mg and 2mg doses of baricitinib achieved a change of at least 75% according to the Eczema Area and Severity Index (EASI) after 16 weeks of treatment, meeting the primary endpoint of the study.

read more

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.